9 Secondary Causes of Osteoporosis That Menopause Unmasks — and Why Your DEXA Scan Is Not the Full Picture
The thing that struck me most researching this was how often women are handed a bisphosphonate prescription or a hormone conversation without anyone ordering a basic blood panel first. If a bone-thinning condition like celiac disease or hyperparathyroidism is sitting underneath, treating only the estrogen piece is like mopping the floor while the tap is still running. You deserve the full picture — and these nine conditions are exactly what to ask your doctor about before assuming menopause is the sole explanation.
Learn more about Rose →Celiac Disease
Undiagnosed or poorly managed celiac disease causes significant bone loss through malabsorption of calcium, vitamin D, and magnesium in the small intestine — nutrients that are foundational to bone remodelling. Population studies estimate that women with celiac disease have bone mineral density roughly 5–10% lower than age-matched controls, and many are not diagnosed until midlife when DEXA scanning begins. A strict gluten-free diet has been shown to partially reverse this bone loss, making diagnosis genuinely life-changing rather than merely academic.
Primary Hyperparathyroidism
The parathyroid glands regulate calcium balance, and when one or more develops a benign adenoma — which becomes more common in women over 50 — parathyroid hormone (PTH) is chronically elevated, pulling calcium out of bone and into the bloodstream. This condition is frequently asymptomatic and is often first suspected when a routine calcium blood test returns high alongside a low DEXA result. Surgical removal of the overactive gland is curative and has been shown in RCTs to stabilise and in some cases improve bone density meaningfully.
Vitamin D Deficiency
Vitamin D is not simply a supplement trend — it is a hormone precursor that directly regulates intestinal calcium absorption and bone mineralisation, and deficiency is strikingly common in women in northern latitudes, those with limited sun exposure, and those with darker skin tones. When vitamin D is low, the body compensates by raising PTH, triggering the same calcium-from-bone mechanism as primary hyperparathyroidism. Crucially, supplementing calcium without first correcting vitamin D deficiency is largely ineffective, which is why serum 25(OH)D testing should precede any bone-protection strategy.
Long-Term Proton Pump Inhibitor (PPI) Use
Proton pump inhibitors — commonly prescribed for reflux, gastritis, and stomach ulcers — reduce stomach acid so effectively that calcium carbonate absorption is significantly impaired, since acidic conditions are required to ionise dietary calcium for uptake. Multiple large observational studies and meta-analyses have found that long-term PPI users (more than one year) have a meaningfully elevated risk of hip and vertebral fracture, independent of age and other risk factors. Women who have been on PPIs for years before their DEXA scan should discuss with their prescribing doctor whether their bone results reflect medication effect as much as hormonal change.
Subclinical Hyperthyroidism and Thyroid Hormone Over-Replacement
Thyroid hormones directly stimulate osteoclast activity — the cells responsible for bone breakdown — and even mildly elevated levels over time accelerate bone resorption beyond the rate at which bone can be rebuilt. Women taking levothyroxine for hypothyroidism are particularly at risk if their dose is slightly too high, suppressing TSH into subclinical hyperthyroid territory without obvious symptoms. Regular TSH monitoring and dose adjustment in women with low bone density is a simple, overlooked step that can meaningfully slow bone loss.
Glucocorticoid Use (Steroids)
Corticosteroids such as prednisolone, used long-term for conditions like asthma, rheumatoid arthritis, inflammatory bowel disease, and lupus, are one of the most potent secondary causes of osteoporosis known — they suppress bone formation, increase bone resorption, and impair intestinal calcium absorption simultaneously. Even inhaled corticosteroids at high doses carry a measurable risk when used over years, which is often underappreciated by both patients and prescribers. Any woman on long-term steroid therapy should have bone density monitoring and a proactive bone-protection conversation, separate from any menopause-related bone risk.
Inflammatory Bowel Disease (Crohn's and Ulcerative Colitis)
Both Crohn's disease and ulcerative colitis reduce bone density through several overlapping mechanisms: chronic intestinal inflammation elevates cytokines that activate bone-resorbing osteoclasts, malabsorption impairs calcium and vitamin D uptake, and the steroid treatments often used add a further layer of bone loss risk. Studies consistently show bone mineral density is lower in IBD patients than in matched controls, and the effect is present even in patients with well-controlled disease. Women who have lived with IBD for years may arrive at menopause with a bone deficit that predates hormonal change by decades.
Early or Premature Ovarian Insufficiency (POI)
Women who experience menopause before age 45 — whether spontaneous, surgical, or chemotherapy-related — lose estrogen's bone-protective effect for significantly more years than those who reach menopause at the average age of 51, resulting in substantially greater cumulative bone loss by the time of any DEXA scan. Premature ovarian insufficiency affects roughly 1 in 100 women under 40, yet bone protection conversations are not always initiated promptly at diagnosis. For these women, the bone loss story is fundamentally different from typical menopause-related decline, and treatment timelines should reflect that difference.
Alcohol Use Disorder and Heavy Chronic Drinking
Chronic heavy alcohol consumption directly suppresses osteoblast function — the bone-building cells — while simultaneously increasing cortisol levels and impairing the liver's conversion of vitamin D to its active form, creating a multi-pathway attack on bone density. Research suggests that women are more vulnerable than men to alcohol-related bone loss at equivalent consumption levels, and the effect begins to accumulate well before menopause. Because alcohol use is often underreported in medical consultations and is not routinely asked about when low bone density is investigated, it remains one of the more consistently missed secondary contributors.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.